Fig. 3From: Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysisCost-effectiveness acceptability curve of FT at different price with different willingness-to-pay threshold. FT Fexapotide triflutate; 5ARI 5-α-Reductase inhibitors; CombRx Combination therapyBack to article page